Aimia Inc. (TSX:AIM)
Canada · Delayed Price · Currency is CAD | Market Cap | 247.47M +8.6% |
| Revenue (ttm) | 511.60M +5.0% |
| Net Income | 34.80M |
| EPS | 0.38 |
| Shares Out | 89.02M |
| PE Ratio | 7.39 |
| Forward PE | 11.12 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 42,747 |
| Average Volume | 28,741 |
| Open | 2.790 |
| Previous Close | 2.780 |
| Day's Range | 2.790 - 2.840 |
| 52-Week Range | 2.290 - 3.440 |
| Beta | 0.12 |
| RSI | 44.13 |
| Earnings Date | Mar 24, 2026 |
About Aimia
Aimia Inc. invests in public and private companies. It operates in three segments: Bozzetto, Cortland International, and Holdings. The company, through its long-term investments, provides specialty chemicals, textiles, and water and dispersion chemical solutions in various applications, including textile, home and personal care, plasterboard, and agrochemical markets; manufactures synthetic fiber ropes, as well as offers netting solutions for maritime and other industrial customers; and manufactures and supplies ropes, slings, and tethers for a... [Read more]
Financial Performance
Financial StatementsNews
Aimia Inc (AIMFF) Q4 2025 Earnings Call Highlights: Navigating Challenges and Capitalizing on ...
Aimia Inc (AIMFF) Q4 2025 Earnings Call Highlights: Navigating Challenges and Capitalizing on Opportunities
Q4 2025 Aimia Inc Earnings Call Transcript
Q4 2025 Aimia Inc Earnings Call Transcript
AIMIA REPORTS FOURTH QUARTER AND FULL YEAR 2025 RESULTS
TORONTO , March 24, 2026 /CNW/ - Aimia Inc. (TSX: AIM) (JSE: AII) ("Aimia" or the "Company"), today reported its financial results for the three-month period and full year ended December 31, 2025. Al...
AIM ImmunoTech Stock Today: AIM Surges 44% on Massive Volume After Patent Approval and Cancer Trial Progress
OCALA, Fla. — Shares of AIM ImmunoTech Inc. (NYSE American: AIM) rocketed higher Wednesday, closing at $1.02, up 31 cents or 43.66%, on extraordinarily heavy trading volume exceeding 183 million share...
Why Is AIM ImmunoTech Stock Gaining Today?
AIM ImmunoTech Inc. (AMEX: AIM) shares moved higher on Wednesday after the company secured full approval for a key cancer-related patent in Japan. • AIM ImmunoTech stock is showing exceptional streng...
AIM ImmunoTech Gains Japanese Patent Approval for Cancer Treatment
AIM ImmunoTech Gains Japanese Patent Approval for Cancer Treatment
AIMIA DECLARES PREFERRED SHARE DIVIDENDS
TORONTO , March 16, 2026 /CNW/ - Aimia Inc. (TSX: AIM) (JSE: AII) today announced that its Board of Directors has declared quarterly dividends on each series of its preferred shares: A quarterly divi...
Verdict parent company GlobalData moves to Main Market of LSE
The move to the LSE's Main Market from the AIM reflects the scale and maturity achieved through GlobalData’s long-term strategy. The post Verdict parent company GlobalData moves to Main Market of LSE ...
Aimia Is Swimming in Cash
The sale of Aimia Inc.'s ( TSX:AIM , Financial) ( AIMFF , Financial) stake in Air Mexico's loyalty program Club Premier will be a huge liquidity event for this Toronto-based asset manager. In fact, fo...